Clinical Trial Update: Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)

View source ↗

Summary

Clinical trial update reporting quality-of-life outcomes in adults with severe chronic obstructive pulmonary disease treated with Daxas (roflumilast).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daxas (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Status: COMPLETED